BMT CTN Protocols

The Blood and Marrow Transplant Clinical Trials Network (BTM CTN) offers a range of multi-institutional phase II and III clinical trial protocols focused directly on improving survival for patients undergoing hematopoietic cell transplantation (HCT). Learn more about these protocols through the links below and check back often for updates.

Open to Accrual

Name	Title	Status
0301	Conditioning Regimens in Unrelated Donor Transplantation for Aplastic Anemia	Open To Accrual (Enrolling)
0501	Single versus Double Cord Blood Transplantation in Children	Open To Accrual (Enrolling)
0502	Reduced-Intensity Conditioning in Transplantation for AML in the Elderly	Open To Accrual (Enrolling)
0601	Transplantation Using Reduced-Intensity Conditioning and Unrelated Donor Graft for Children with Severe Sickle Cell Disease	Open To Accrual (Enrolling)
0701	Transplantation using Reduced-Intensity Conditioning for Relapsed Follicular Lymphoma	Open To Accrual (Enrolling)
0702	Autologous Transplantation with/without Consolidation versus Tandem Autologous Transplantation with Lenalidomide Maintenance	Open To Accrual (Enrolling)
0801	Randomized Trial using Sirolimus with Other Agents for Chronic GVHD	Open To Accrual (Enrolling)
0802	Corticosteroids with Mycophenolate Mofetil versus Corticosteroids with Placebo as Initial Systemic Treatment of Acute GVHD	Open To Accrual (Enrolling)
0803	High Dose Chemotherapy with Autologous Stem Cell Rescue for Aggressive B cell Lymphoma and Hodgkin Lymphoma in HIV-infected Patients	Open To Accrual (Enrolling)
0804	Phase II Study of Reduced-intensity Allogeneic Stem Cell Transplantation for High Risk Chronic Lymphocytic Leukemia	Open To Accrual (Enrolling)
0902	Peri-transplant Stress Management	Open To Accrual (Enrolling)
0901	Myeloablative versus Nonmyeloablative Transplant Conditioning in Patients with Myelodysplastic Syndrome or Acute Myelogenous Leukemia	Open To Accrual (Enrolling)

Anticipated for Release

Name	Title	Status
0805	Hyper-CVAD and Dasatinib with or without Allogeneic Stem Cell transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or Bcr-Abl Positive Acute Lymphoblastic Leukemia	Anticipated For Release
0903	Allogeneic Transplantation in HIV+ Patients	Anticipated For Release

Under Development

Name	Title	Status

Closed to Accrual

Name	Title	Status
0402	0402Tacrolimus/Sirolimus versus Tacrolimus/Methotrexate as GVHD Prophylaxis	Closed To Accrual
0403	Etanercept for Idiopathic Pneumonia Syndrome	Closed To Accrual
0101	Fluconazole versus Voriconazole after Allogeneic Transplantation	Closed To Accrual
0102	Autologous/Autologous versus Autologous/Allogeneic Transplantation for Multiple Myeloma	Closed To Accrual
0201	Peripheral Blood versus Bone Marrow Grafts from Unrelated Donors	Closed To Accrual
0202	Autologous versus Nonmyeloablative Allogeneic Transplantation for Follicular Lymphoma	Closed To Accrual
0302	Randomized Trial of Acute GVHD Therapies	Closed To Accrual
0303	T-Cell Depleted Peripheral Blood Stem Cell Transplantation for AML	Closed To Accrual
0401	Rituxan/BEAM versus Bexxar/BEAM with Autologous Transplantation in Diffuse Large Cell Lymphoma	Closed To Accrual
0603	Haploidentical Transplantation with Reduced-Intensity Conditioning	Closed To Accrual
0604	Double Cord Blood Transplantation with Reduced-Intensity Conditioning	Closed To Accrual
0703	Tandem Autologous Transplantation for Recurrent Hodgkin Disease	Closed To Accrual
0704	Maintenance Therapy with CC-5013 or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma	Closed To Accrual